Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
Patient received first dose of Rabavert for pre-exposure and did not receive the second dose on day seven; Case reference number US-BN-2024-002069 is a spontaneous case initially received from a nurse via Med Communication (reference number: USBAV24-1402) on 18-Jun-2024 and concerns a female patient. The patient's medical history and concomitant medication were not provided. On 20-May-2024, the patient was vaccinated with the first dose of Rabavert (batch number: unknown) at an unknown dose, via unknown route and site of administration for pre-exposure vaccination. As reported, patient did not get the second dose on day seven (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event Rabavert. No further information was provided.; Reporter's Comments: A female patient was vaccinated with the first dose of Rabavert for pre-exposure vaccination. As reported, patient did not get the second dose on day seven, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event Rabavert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient was vaccinated with the first dose of Rabavert for pre-exposure vaccination. As reported, patient did not get the second dose on day seven, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event Rabavert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.